Europe Mass Spectrometry Market

The Europe mass spectrometry market is estimated to reach USD 2.83 billion by 2031, up from USD 1.83 billion in 2025, at a CAGR of 7.6% during the forecast period.

Beyond instrument replacement, the mass spectrometry market growth is being driven by three structural shifts: the push toward precision diagnostics and personalized therapies, the tightening of environmental and food safety regulations under the EU Green Deal agenda, and a broader move toward digital, data-centric laboratory operations. Together, these forces are cementing mass spectrometry as a “must-have” core platform across clinical, pharmaceutical, environmental, and food testing ecosystems rather than a niche research tool. Also, regulation and risk management are acting as powerful accelerators rather than constraints. Continuous updates and food safety frameworks, rising scrutiny of PFAS and other persistent contaminants, and stricter limits on residues in water, soil, and the food chain are forcing laboratories to demonstrate trace-level quantification with strong audit trails.

To know about the assumptions considered for the study download the pdf brochure

Europe is home to several leading global companies in mass spectrometry, alongside a robust network of regional specialists that leverage their capabilities to package instruments, informatics, automation, and service contracts into comprehensive lifecycle value propositions for reference laboratories, innovative pharmaceutical and biopharmaceutical companies, contract research organizations (CROs), and contract development and manufacturing organizations (CDMOs). Concurrently, tier 2 and tier 3 European enterprises, as well as food and beverage companies, are successfully establishing profitable niches through application-specific systems, tailored methodologies, and responsive local service. The successful strategies within this market revolve around three critical components: aligning product portfolios with high-growth applications (such as clinical liquid chromatography-mass spectrometry (LC-MS), impurity profiling, per- and polyfluoroalkyl substances (PFAS), and trace organics); closely integrating mass spectrometry with laboratory information management systems (LIMS) and automation to minimize the total cost per test; and fostering strategic partnerships with key accounts to collaboratively develop methodologies that can be swiftly scaled throughout the region.

Agilent Technologies, Inc. (US)

Agilent Technologies provides a broad portfolio of LC-MS, GC-MS, and ICP-MS systems and maintains a strong market presence across Europe. The company actively engages with the scientific and clinical community through participation in key regional events such as BSMS 2025 in Mons, the Innovation Tour Luxembourg, the 10th Scientific Meeting of MolecularDiagnostics.be, and BSAC–NVC in Belgium. These initiatives highlight Agilent’s commitment to showcasing advancements in LC, GC, and MS technologies. In addition, the company continues to strengthen its position through inorganic growth strategies, including mergers and acquisitions, partnerships, collaborations, and regional expansions.

Thermo Fisher Scientific, Inc. (US)

Thermo Fisher Scientific provides an extensive portfolio of solutions for laboratory research, clinical science, manufacturing, and related fields, with its analytical instruments division offering a wide range of mass spectrometry platforms. The company continues to strengthen its footprint across Europe—particularly in the UK, Netherlands, Spain, Italy, Germany, France, and Belgium—through the expansion of IVDR-compliant, automation-enabled clinical mass spectrometry systems, following the success of earlier regional launches such as the EXENT platform. While EXENT represented a significant advancement in integrated MS workflows for diagnosing monoclonal gammopathies, Thermo Fisher is now focusing on developing high-throughput, regulated MS technologies, enhancing end-to-end automation from sample prep to data analysis, and deepening collaborations with hospitals and reference laboratories.

Analytik Jena GmbH & Co. KG (Germany)

Analytik Jena provides instruments and products in analytical measuring technology and life sciences applications. The company develops and produces analytical & bioanalytical equipment, reagents for molecular sample preparation & diagnostics, system solutions for laboratory automation, and industry-specific software solutions. Analytik Jena ensures reliable ultratrace-to-high-concentration elemental measurements across a wide range of industries, including environmental monitoring, food and agriculture, geology, pharmaceuticals, and energy. By continuously advancing plasma ionization technology, interference management, ion optics, and quadrupole performance, the company delivers ICP-MS platforms that offer superior sensitivity, long-term stability, and high throughput.

Related Reports:

Europe Mass Spectrometry Market by Component (Detector, Mass Analyzer, Ion Source, Vacuum System), Product (Triple Quad, Q-ToF, FTMS, Quad, ToF), Application (Omics, Environment, Pharma, Biopharma) - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com